Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 21, 2013

Primary Completion Date

May 22, 2019

Study Completion Date

May 12, 2021

Conditions
Advanced Malignant Solid NeoplasmHIV InfectionMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmUnresectable Solid Neoplasm
Interventions
DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (20)

10461

Montefiore Medical Center-Einstein Campus, The Bronx

Montefiore Medical Center-Weiler Hospital, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Siteman Cancer Center at Washington University, St Louis

Washington University School of Medicine, St Louis

70503

Louisiana State University, Lafayette

77009

Thomas Street Clinic, Houston

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

Ben Taub General Hospital, Houston

90035

UCLA Center for Clinical AIDS Research and Education, Los Angeles

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

92093

UC San Diego Moores Cancer Center, La Jolla

92103

UC San Diego Medical Center - Hillcrest, San Diego

96813

University of Hawaii Cancer Center, Honolulu

98101

Virginia Mason Medical Center, Seattle

98104

Harborview Medical Center, Seattle

98109

Fred Hutchinson Cancer Research Center, Seattle

02118

Boston Medical Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01822522 - Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus | Biotech Hunter | Biotech Hunter